Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects Article uri icon

Overview

MeSH Major

  • Antigens, Differentiation
  • Calreticulin
  • Cell Cycle Proteins
  • Protein Phosphatase 1

abstract

  • Retrospective clinical data indicate that cardiac glycosides (CGs), notably digoxin, prolong the survival of carcinoma patients treated with conventional chemotherapy. CGs are known to influence the immune response at multiple levels. In addition, recent results suggest that CGs trigger the immunogenic demise of cancer cells, an effect that most likely contributes to their clinical anticancer activity.

publication date

  • December 2012

Research

keywords

  • Article

Identity

Digital Object Identifier (DOI)

  • 10.4161/onci.21684

Additional Document Info

start page

  • 1640

end page

  • 1642

volume

  • 1

number

  • 9